Get notified of page updates

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. (OlympiA)

Clinicaltrials.gov identifier:
NCT02032823

Study Contact Information:

  • Principal Investigators: Andrew Tutt, Doctor of Medicine Integrated Cancer Centre Guy's Hospital, King's College, London School of Medicine, London, UK; Bella Kaufman, Sheba Medical Center, 1 Tel Hashomer, Israel; Judy Garber, Doctor of Medicine Harvard Medical School, Center for Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston; MA; Charles Geyer, Doctor of Medicine Virginia Commonwealth University Massey Cancer Center, Richmond, VA 
PRINTER FRIENDLY PAGE
Overview
Who Can Join
Contact
Glossary on
off

About the Study

The OlympiA trial is the first major study to test the olaparib (Lynparza) for people with mutation-associated breast cancer in the setting (after surgery) for people with earlier-stage ( 2 or stage 3) cancers. OlympiA is a phase III clinical trial looking at the safety and effectiveness of for women with stage 2 or 3 breast cancer with a BRCA mutation after they have completed standard therapy.

The OlympiA trial has now completed enrollment. Interim results from OlympiA were presented at the 2021 ASCO Annual Symposium. 

This Study is Open To:

The study is no longer enrolling patients. 

This Study is NOT Open To:

The study is no longer enrolling patients. 

Study Contact Information:

  • Principal Investigators: Andrew Tutt, Doctor of Medicine Integrated Cancer Centre Guy's Hospital, King's College, London School of Medicine, London, UK; Bella Kaufman, Sheba Medical Center, 1 Tel Hashomer, Israel; Judy Garber, Doctor of Medicine Harvard Medical School, Center for Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston; MA; Charles Geyer, Doctor of Medicine Virginia Commonwealth University Massey Cancer Center, Richmond, VA 

Clinicaltrials.gov identifier:
NCT02032823

Study Contact Information:

  • Principal Investigators: Andrew Tutt, Doctor of Medicine Integrated Cancer Centre Guy's Hospital, King's College, London School of Medicine, London, UK; Bella Kaufman, Sheba Medical Center, 1 Tel Hashomer, Israel; Judy Garber, Doctor of Medicine Harvard Medical School, Center for Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston; MA; Charles Geyer, Doctor of Medicine Virginia Commonwealth University Massey Cancer Center, Richmond, VA 
PRINTER FRIENDLY PAGE